Abeona Therapeutics Inc Watch

from 10-Q 5 pages 1. You Remain a Full-Time, Active Employee of Abeona Through the End of the Retention Period. 2. Your Performance Has Been Satisfactory and Meets Expectations, as Determined in Abeona’s Sole Discretion, From the Date of This Letter Through the End of the Retention Period. 3. You Do Not Receive a Disciplinary Action, Such as a Written Warning, During the Retention Period. 4. You Are Actively and Continuously Employed by Abeona Through Each of the Bonus Payments Dates Described Herein, Including the Last Day of the Retention Period. 5. You Have Not Given Notice of Your Intent to Resign From Employment on or Before the Last Day of the Retention Period. 6. Abeona Therapeutics Has Not Given You Notice of Its Intent to Terminate Your Employment on or Before the Last Day of the Retention Period

from 10-Q 5 pages 1. You Remain a Full-Time, Active Employee of Abeona Through the End of the Retention Period. 2. Your Performance Has Been Satisfactory and Meets Expectations, as Determined in Abeona’s Sole Discretion, From the Date of This Letter Through the End of the Retention Period. 3. You Do Not Receive a Disciplinary Action, Such as a Written Warning, During the Retention Period. 4. You Are Actively and Continuously Employed by Abeona Through Each of the Bonus Payments Dates Described Herein, Including the Last Day of the Retention Period. 5. You Have Not Given Notice of Your Intent to Resign From Employment on or Before the Last Day of the Retention Period. 6. Abeona Therapeutics Has Not Given You Notice of Its Intent to Terminate Your Employment on or Before the Last Day of the Retention Period

from 10-Q 5 pages 1. You Remain a Full-Time, Active Employee of Abeona Through the End of the Retention Period. 2. Your Performance Has Been Satisfactory and Meets Expectations, as Determined in Abeona’s Sole Discretion, From the Date of This Letter Through the End of the Retention Period. 3. You Do Not Receive a Disciplinary Action, Such as a Written Warning, During the Retention Period. 4. You Are Actively and Continuously Employed by Abeona Through Each of the Bonus Payments Dates Described Herein, Including the Last Day of the Retention Period. 5. You Have Not Given Notice of Your Intent to Resign From Employment on or Before the Last Day of the Retention Period. 6. Abeona Therapeutics Has Not Given You Notice of Its Intent to Terminate Your Employment on or Before the Last Day of the Retention Period

from 8-K 50 pages Securities Purchase Agreement

from 8-K 38 pages Securities Purchase Agreement

from 10-Q 55 pages Specific Terms in This Agreement Have Been Redacted Because Such Terms Are Both Not Material and Are of a Type That Abeona Therapeutics Inc. Treats As

from 10-Q 15 pages Via Email February 28, 2022 This Letter Agreement Sets Forth the Terms of Your Employment as Senior Vice President, Chief Financial Officer, Effective March 7, 2022 (The “Effective Date”). 1. Duties; Best Efforts

from 8-K 18 pages Registration Rights Agreement

from 8-K 41 pages Securities Purchase Agreement

from 10-K 10 pages Certain Identified Information Has Been Excluded From This Exhibit Pursuant to Item 601(b)(10)(iv) of Regulation S-K Because Such Information Both (I) Is Not Material and (II) Would Likely Cause Competitive Harm if Publicly Disclosed. Excluded Information Is Indicated With Brackets and Asterisks. Settlement Agreement and Mutual Release

from 10-K 14 pages September 16, 2021 This Letter Agreement Sets Forth the Terms of Your Employment as Svp, General Counsel, Effective September 20, 2021 (The “Effective Date”). 1. Duties; Best Efforts

from 10-K 16 pages October 6, 2021 This Letter Agreement Sets Forth the Terms of Your Employment as Chief Executive Officer (CEO) of Abeona Therapeutics Inc. (The “Company”) Effective October 15, 2021 (The “Effective Date”). 1. Duties; Best Efforts

from 10-Q 14 pages August 10, 2021 This Letter Agreement Sets Forth the Terms of Your Employment as Svp, Chief Financial Officer, Effective August 10, 2021 (The “Effective Date”). 1. Duties; Best Efforts

from 10-Q 16 pages March 19, 2021 I Am Pleased to Offer You the Position of Chief Executive Officer of Abeona Therapeutics, Inc. (The “Company”) Effective March 19, 2021 (The “Effective Date”). 1. Duties; Best Efforts

from 10-Q 15 pages January 27, 2021 C/O Michael Amoroso Dear Michael, This Letter Agreement Sets Forth the Terms of Your Employment as Evp, Chief Operating Officer Effective January 27, 2021 (The “Effective Date”). 1. Duties; Best Efforts

from 8-K 14 pages October 25, 2020 C/O Michael Amoroso Dear Michael, This Letter Agreement Sets Forth the Terms of Your Employment as Svp, Chief Operating Officer Effective November 1, 2020 (The “Effective Date”). 1. Duties; Best Efforts

from 8-K 15 pages Indemnification Agreement

from 10-Q 1 page Amendment No. 3 to Separation Agreement April 14, 2020

from 8-K 8 pages June 18, 2020 This Letter Agreement Sets Forth the Terms of Your Employment as Vp, Chief Accounting Officer, Effective June 16, 2020 (The “Effective Date”). 1. Duties; Best Efforts

from 10-Q 1 page Amendment No. 2 to Separation Agreement March 31, 2020